Company announcement - No. 24 / 2026
Transactions in Zealand Pharma shares and/or related securities by persons
discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, June 10, 2026 - Zealand Pharma A/S ("the Company" or
"Zealand Pharma") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company
transforming the future of metabolic health, has received information on
transactions in Zealand Pharma's shares or related securities conducted by
persons discharging managerial responsibilities and/or their closely associated
persons and hereby publishes the information on such transactions.
Please see the attached file(s).
About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on
advancing medicines for obesity and metabolic health. Combining more than 25
years of peptide R&D expertise with a proprietary data platform that leverages
advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era
in obesity and metabolic health. To date, more than 10 Zealand Pharma invented
drug candidates have entered clinical development, of which two products have
reached the market and three candidates are in late-stage development. The
Company has collaborations with global pharmaceutical and biotechnology partners
for research, development, and commercialization. Founded in 1998, Zealand
Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston,
Massachusetts. Learn more at www.zealandpharma.com
(http://www.zealandpharma.com).
Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com
Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
Email: rjamesowens@zealandpharma.com
Andreas Hylleberg Mølleskov (Media)
Director, External Communications
Zealand Pharma
Email: ahylleberg@zealandpharma.com
Â